Cigna Corporation (CI)
Healthcare · Medical - Healthcare Plans · Data as of 2026-09-01
Bottom line
CI is trading at a discount to its history, near its historical resistance zone, and recent volume shows no clear direction. The picture is mixed, so it may be worth watching rather than acting on. Past patterns are not a guarantee of future results.
Valuation — Trading at a discount to its history (Green)
CI trades at 12× earnings, below its own 5-year average of 15× and below similar healthcare companies we track (29×, 52 peers). Historically this has been on the cheaper side for the stock. It also generates strong cash: a free-cash-flow yield of about 12%. Its current multiple sits around the 7th percentile of its own last five years — toward the low end of its own range. Its fundamentals scored 7 of 9 on a standard year-over-year quality checklist — most of the underlying trends improved last fiscal year.
Price zones — Near its historical resistance zone (Red)
At $283.06, the stock is close to the upper end of its recent range. Over the past year CI has traded between $239.51 and $315.47; its historical support zone sits near $279.38 and resistance near $283.31. It is above one of its moving averages and below the other — a mixed trend picture.
52-week range $239.51–$315.47 · 50-day average $283.31 · 200-day average $279.38
Money flow — No clear direction (Yellow)
Buying and selling volume in CI have been fairly balanced recently, with no strong accumulation or distribution pattern. Volume on up days has been about 1.0× volume on down days over the last 30 sessions.
About the company
Cigna Group, established in 1792 and headquartered in Bloomfield, Connecticut, provides insurance products and related services across the United States. The company operates through two primary segments. Its Evernorth division offers a comprehensive array of coordinated and specialized health solutions, including pharmacy services, benefits administration, care management and delivery, and advanced intelligence solutions.
一句话结论
CI 相对自身历史处于折价水平，接近其历史阻力区，近期成交量没有明确方向。整体情况好坏参半，也许更适合先观察，而不是急于行动。过去的形态并不能保证未来的结果。
估值 — 相对自身历史处于折价水平
CI 目前的市盈率为 12×，低于其自身 5 年平均的 15×，并且低于我们追踪的同类Healthcare公司（29×，52 家）。从历史来看，这属于该股较便宜的一侧。它同时产生充沛的现金：自由现金流收益率约为 12%。它当前的估值倍数大约位于自身过去五年分布的第 7 百分位——处于自身区间的偏低位置。在一套标准的逐年基本面核对清单上，它 9 项中通过了 7 项——上一财年多数底层趋势在改善。
价格区间 — 接近其历史阻力区
目前价格为 $283.06，接近其近期区间的上沿。过去一年 CI 的价格在 $239.51 到 $315.47 之间波动；其历史支撑区在 $279.38 附近，阻力区在 $283.31 附近。它位于其中一条均线上方、另一条下方——趋势信号并不一致。
资金流向 — 方向不明确
CI 近期的买卖成交量大致均衡，没有明显的吸筹或派发形态。过去 30 个交易日，上涨日的成交量约为下跌日的 1.0×。
UnderTheLight 用直白的语言解释股票——估值、价格区间与资金流向。它只描述数据，不构成任何投资建议。
UnderTheLight explains stocks in plain English — valuation, price zones and money flow as traffic lights, recomputed nightly. It describes data; it is not investment advice and never recommends a trade.